Wood Foundation to conduct research on the impact of fatigue in individuals diagnosed with craniopharyngioma, a type of brain tumor. The study aims to gather insights directly from patients and ...

New registry study to focus on impact of fatigue in people with craniopharyngiomaBOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...

Wood Foundation, a patient advocacy organization for survivors of craniopharyngioma and hypothalamic-pituitary brain tumors, today announced a new research collaboration to study the impact of ...

Abbie Keet, 24, developed a golf ball-sized tumour and started having eye problems when she was pregnant with her first child ...

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...

Rhythm Pharmaceuticals (RYTM) and the Raymond A. Wood Foundation announced a new research collaboration to study the impact of fatigue on ...

Brain surgery at age 11 sent her into menopause and hormonal weight gain. She loses 130 lbs with yoga, strength training, ...

Rhythm Pharma gets orphan drug designation for its setmelanotide to treat hypothalamic obesity in Japan: Boston Friday, March 21, 2025, 16:00 Hrs [IST] Rhythm Pharmaceuticals, Inc ...

A woman has shared her horrifying ordeal after her "blurry vision" during pregnancy was actually caused by a golf ball-sized ...